Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE13 study of zenagamtide for weight loss in Asian adults with overweight or obesity
jRCT2051260208Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2027
- Modality
- Small Molecules, Peptides
01
Overview
Single-arm trial of amycretin in obesity and Overweight, sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight from baseline to end of treatment. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
amycretin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051260208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260208.